Frantz v. Secretary of Health and Human Services

CourtUnited States Court of Federal Claims
DecidedAugust 7, 2019
Docket13-158
StatusPublished

This text of Frantz v. Secretary of Health and Human Services (Frantz v. Secretary of Health and Human Services) is published on Counsel Stack Legal Research, covering United States Court of Federal Claims primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Frantz v. Secretary of Health and Human Services, (uscfc 2019).

Opinion

In the United States Court of Federal Claims OFFICE OF SPECIAL MASTERS

********************** SIERRA FRANTZ, * * No. 13-158V Petitioner, * Special Master Christian J. Moran * v. * Filed: June 24, 2019 * SECRETARY OF HEALTH * Attorneys’ Fees and Costs, reasonable AND HUMAN SERVICES, * basis * Respondent. * **********************

Ronald C. Homer & Christina Ciampolillo, Conway, Homer, P.C., Boston, MA, for Petitioner; Daniel Principato & Debra A. Filteau Begley, United States Dep’t of Justice, Washington, DC, for Respondent.

PUBLISHED DECISION AWARDING ATTORNEYS’ FEES AND COSTS1

Sierra Frantz claimed that vaccines caused her to develop a demyelinating condition, later diagnosed as multiple sclerosis, a condition marked by lesions in the central nervous system. She retained two experts to assist her, and the Secretary matched with two experts. In a ruling from the bench, the undersigned found that the evidence showed that Ms. Frantz was already suffering from pre- clinical multiple sclerosis when she received the allegedly causal vaccines. The primary evidence supporting this finding was an article Francois Cotton wrote in 2003 about the duration of lesion enhancement. Because Ms. Frantz had at least one lesion in her brain that probably existed before the vaccinations, the vaccines

1 The E-Government Act, 44 U.S.C. § 3501 note (2012) (Federal Management and Promotion of Electronic Government Services), requires that the Court post this decision on its website. This means the decision will be available to anyone with access to the internet. Pursuant to Vaccine Rule 18(b), the parties have 14 days to file a motion proposing redaction of medical information or other information described in 42 U.S.C. § 300aa-12(d)(4). could not have caused the demyelinating condition. Thus, Ms. Frantz was not awarded compensation. Following this denial of compensation, Ms. Frantz moved for final attorneys’ fees and costs. She requested $326,914.44, later amended to $352,451.91. The Secretary countered that because Ms. Frantz had not established a reasonable basis for the claim set forth in her petition, Ms. Frantz should receive no attorneys’ fees and costs. The parties subsequently developed their positions on reasonable basis and then participated in an oral argument on that issue. For the reasons explained below, she is awarded $135,187.59.

* * *

I. Background A. Cotton and W.C. The Cotton article was a key aspect of the decision denying Ms. Frantz compensation.2 Cotton was discussed in a case highly similar to Ms. Frantz’s case, W.C. v. Sec’y of Health & Human Servs., No. 07-456V, 2011 WL 4537877 (Fed. Cl. Spec. Mstr. Feb. 22, 2011), mot. for rev. denied on relevant grounds, 100 Fed. Cl. 440 (2011), aff'd, 704 F.3d 1352 (Fed. Cir. 2013). Thus, this background material is set forth to provide context for the developments in Ms. Frantz’s case.

Like Ms. Frantz, W.C. was a healthy individual who received a flu vaccination, developed neurologic symptoms, and was diagnosed with multiple sclerosis. W.C., 2011 WL 4537877, at *2-3. Represented by the same law firm that represents Ms. Frantz, W.C. alleged that the flu vaccination caused him to develop multiple sclerosis. W.C. retained Carlo Tornatore, a neurologist, who offered an opinion that the vaccine did, in fact, cause W.C. to develop multiple sclerosis. The Secretary presented the view of Arun Venkatesan, also a neurologist. Dr. Venkatesan opined that the presence of non-enhancing lesions on W.C.’s initial MRI meant that the lesions must have formed before the vaccination. The parties were instructed to present evidence about how long lesions enhance on MRIs.

The undersigned found that the Cotton article was the most informative study. In Cotton, the researchers performed MRI scans on a collection of patients

2 Exhibit D, Tab 3 - Francois Cotton et al., MRI Contrast Uptake in New Lesions in Relapsing-remitting MS Followed at Weekly Intervals, 60 Neurology 640 (2003).

2 every week. This level of regularity made the Cotton research more granular than earlier studies in which the MRIs were repeated monthly. Cotton and colleagues found that half of the lesions studied were enhancing after 14 days.

The metric from Cotton was then used to evaluate the MRI that W.C. underwent 17 days after vaccination. W.C.’s initial MRI showed six non- enhancing lesions and no enhancing lesions. The presence of non-enhancing lesions, combined with the knowledge about the duration of enhancement Cotton supplied, was the basis for Dr. Venkatesan’s opinion that W.C.’s lesions pre-dated the vaccination.

The (undersigned) special master credited Dr. Venkatesan’s opinion and found Dr. Tornatore’s contrary opinion unpersuasive. The undersigned found that W.C.’s first MRI was taken close enough in time to the vaccination that at least one lesion of the six lesions should have been in the enhancing phase. However, W.C.’s lesions were not enhancing, which implies that the lesions were beyond the initial enhancing phase and could not have been caused by the vaccination. Thus, the (undersigned’s) decision found that W.C.’s lesions pre-existed the vaccination and the vaccination could not have caused the lesions.

Still represented by the same attorneys, W.C. filed a motion for review. The Court of Federal Claims evaluated whether the factual finding regarding the duration of lesion enhancement was arbitrary or capricious. W.C., 100 Fed. Cl. 440, 451 (2011), aff'd, 704 F.3d 1352 (Fed. Cir. 2013). The Court described the special master’s interpretation of the range of enhancement for lesions in the Cotton article and did not dispute that interpretation. Id. at 451-53. The Court agreed that the lesion enhancement timeline proposed by W.C. was possible but also stated that the special master’s finding of a longer enhancement timeline was “quite possible.” Id. at 453. The Court found that the special master’s finding on the duration of lesion enhancement was not arbitrary or capricious. Id. at 461. The Court, consequently, denied the motion for review.

W.C. next appealed to the Federal Circuit. The Federal Circuit again evaluated the special master’s finding on the duration of lesion enhancement under the arbitrary or capricious standard. W.C., 704 F.3d 1352, 1355 (Fed. Cir. 2013). The Federal Circuit agreed with the special master’s explanation of the enhancement timeline for lesions described in Cotton. Id. at 1359. Further, the Federal Circuit found that the special master’s finding on the duration of lesion enhancement was not arbitrary or capricious and that the special master’s finding that W.C.’s lesions pre-existed the vaccination was also neither arbitrary nor capricious. Id. at 1359-60. Thus, the Federal Circuit affirmed the judgment 3 denying compensation. Id. at 1361. The Federal Circuit issued its opinion on January 13, 2013, a few months before Ms. Frantz filed her petition. B. Brief Factual Summary for Ms. Frantz

At twelve years old, Ms. Frantz had previously received all her scheduled vaccinations and was generally healthy. On August 6, 2010, Ms. Frantz received the tetanus-diphtheria-acellular pertussis (“Tdap”) and hepatitis A vaccinations. On August 9, 2010, Ms. Frantz’s mother called her doctor and reported that Ms. Frantz had been off-balance, dizzy and sluggish since August 7, 2010, and later went with Ms. Frantz to the emergency room for these neurologic symptoms.

Ms. Frantz’s neurologic symptoms worsened, and she underwent her first MRI on August 12, 2010. This first MRI revealed one enhancing lesion on her brain stem as well as two non-enhancing lesions in her upper medulla and left periventricular region.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Blum v. Stenson
465 U.S. 886 (Supreme Court, 1984)
Missouri v. Jenkins Ex Rel. Agyei
491 U.S. 274 (Supreme Court, 1989)
Avera v. Secretary of Health and Human Services
515 F.3d 1343 (Federal Circuit, 2008)
Brenda Bennett v. Department of the Navy
699 F.2d 1140 (Federal Circuit, 1983)
George E. Schuenemeyer, III v. United States
776 F.2d 329 (Federal Circuit, 1985)
Chuisano v. Secretary of Health and Human Services
116 Fed. Cl. 276 (Federal Claims, 2014)
Guerrero v. Secretary of Health and Human Services
124 Fed. Cl. 153 (Federal Claims, 2015)
Nova Chemicals Corporation v. Dow Chemical Company
856 F.3d 1012 (Federal Circuit, 2017)
Carter v. Secretary of Health and Human Services
132 Fed. Cl. 372 (Federal Claims, 2017)
Simmons v. Secretary of Health & Human Services
875 F.3d 632 (Federal Circuit, 2017)
Afge Local 3599 v. E.E.O.C.
920 F.3d 794 (Federal Circuit, 2019)
Guy v. Secretary of Health & Human Services
38 Fed. Cl. 403 (Federal Claims, 1997)
W.C. v. Secretary of Health & Human Services
100 Fed. Cl. 440 (Federal Claims, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Frantz v. Secretary of Health and Human Services, Counsel Stack Legal Research, https://law.counselstack.com/opinion/frantz-v-secretary-of-health-and-human-services-uscfc-2019.